Delivery Order SPE2DB24D3014-SPE2DB25FKUTC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 300 mg/2 mL pen injections with a ceiling value of $14,525.26. This firm fixed-price delivery order, which is expected to be completed by August 4, 2025, was competitively awarded with no set-aside designation. The product will be delivered to the prime contractor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a $54,501.62 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 27, 2025, with ultimate completion by August 28, 2025. This firm fixed-price, competitively awarded contract—without set-aside designation—will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis, asthma, and chronic...
- The Defense Logistics Agency awarded a $17,929.57 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside delivery order with a completion date of September 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a monoclonal antibody used to treat conditions including moderate-to-severe eczema, asthma, and chronic rhinosinusitis, making...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $17,844.05 to supply Dupixent 300 mg/2 ml pen injectors, with a completion deadline of September 8, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat eczema, asthma, and other inflammatory conditions, demonstrating...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,616.79 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors valued at $15,091.12, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. Dupixent is a prescription biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions,...
- The Defense Logistics Agency awarded a delivery order valued at $14,005.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injectors on August 21, 2025, with completion scheduled for August 22, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions such as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,467.88 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL quantity) on June 2, 2025, with an ultimate completion date of June 3, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Dupixent 300 mg/2 ml pen injections with a ceiling value of $11,758.26. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 8, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various inflammatory conditions,...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKUTCDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,066.05 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on September 18, 2025, with completion scheduled for September 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and other allergic conditions, making this a critical pharmaceutical supply requirement for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 global pharmaceutical support vehicle that extends through December 2026. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support military healthcare programs worldwide, serving the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. AmerisourceBergen's substantial contract portfolio and established relationship with DLA demonstrate the company's capability to meet federal procurement requirements for specialized biologic medications and other critical pharmaceutical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.1k | 9/18/25 |